NCT04952727View on ClinicalTrials.gov

Study on Sequential Immunization of Inactivated COVID-19 Vaccine and Recombinant COVID-19 Vaccine (Ad5 Vector) in Elderly Adults

PHASE4CompletedINTERVENTIONAL
Enrollment

300

Participants

Timeline

Start Date

August 26, 2021

Primary Completion Date

November 26, 2021

Study Completion Date

May 15, 2022

Conditions
COVID-19
Interventions
BIOLOGICAL

Recombinant SARS-CoV-2 Ad5 vectored vaccine

This vaccine contains 5×10\^10 virus particles of recombinant replication defective human type 5 adenovirus expressing SARS-CoV-2 S protein, which is produced by CanSino Biologics Inc. It is a liquid dosage form, 0.5 ml / bottle.

BIOLOGICAL

Inactive SARS-CoV-2 vaccine (Vero cell)

This vaccine contains 600 SU of SARS-CoV-2 antigen, which is produced by Sinovac Research \& Development Co., Ltd. 0.5 ml / bottle.

Trial Locations (1)

Unknown

Jiangsu Provincial Center for Diseases Control and Prevention, Nanjing

Sponsors

Collaborators (1)

CanSino Biologics Inc.
All Listed Sponsors
collaborator

CanSino Biologics Inc.

INDUSTRY

lead

Jiangsu Province Centers for Disease Control and Prevention

NETWORK

NCT04952727 - Study on Sequential Immunization of Inactivated COVID-19 Vaccine and Recombinant COVID-19 Vaccine (Ad5 Vector) in Elderly Adults | Biotech Hunter | Biotech Hunter